Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.
About Xenetic Biosciences Inc.
Xenetic Biosciences Inc. (NASDAQ: XBIO) is a clinical-stage biopharmaceutical company dedicated to advancing innovative immuno-oncology technologies and next-generation biologic therapeutics. With a focus on addressing hard-to-treat cancers and other severe medical conditions, Xenetic leverages its proprietary platforms to develop transformative therapies that improve patient outcomes.
Core Technologies
The company's flagship technology, the DNase-based oncology platform, is designed to target neutrophil extracellular traps (NETs), which are implicated in cancer progression, metastasis, and resistance to existing therapies. By reducing NETs burden in the tumor microenvironment, Xenetic's DNase platform enhances the efficacy of immunotherapies, adoptive cell therapies, and chemotherapies. This technology is being developed as an adjunctive treatment for pancreatic carcinoma, colorectal cancer, and other locally advanced or metastatic solid tumors.
Another key innovation is the PolyXen™ platform, which improves the pharmacological properties of biologic drugs, including extended half-life and reduced immunogenicity. This platform is being utilized in collaborations with global pharmaceutical companies to develop next-generation biologics, such as polysialylated blood coagulation factors.
Pipeline and Partnerships
Xenetic's pipeline includes investigational therapies targeting significant unmet needs in oncology. The company is advancing its systemic DNase program into clinical trials, focusing on its potential as an adjunctive therapy in combination with chemotherapy and immune checkpoint inhibitors. Preclinical studies have demonstrated encouraging results, including enhanced tumor suppression, improved T-cell activation, and prolonged survival in animal models.
Collaborations play a pivotal role in Xenetic's strategy. The company has established partnerships with institutions such as the University of Virginia and PeriNess Ltd., leveraging their expertise to accelerate preclinical and clinical development. Additionally, Xenetic's sublicense agreement with Takeda Pharmaceuticals for the PolyXen platform generates royalty revenues, supporting its broader research and development efforts.
Market Position and Competitive Edge
Operating within the highly competitive oncology sector, Xenetic differentiates itself through its focus on NET-targeting therapies and its ability to enhance existing treatment paradigms. By addressing the immunosuppressive tumor microenvironment and improving the efficacy of established therapies, the DNase platform holds the potential to transform treatment outcomes for patients with aggressive and resistant cancers.
The company's emphasis on collaboration, coupled with its proprietary technologies, positions it as a key innovator in the field of immune-oncology. Its strategic focus on hard-to-treat cancers underscores its commitment to addressing significant unmet medical needs.
Conclusion
With a robust pipeline, cutting-edge technologies, and strategic partnerships, Xenetic Biosciences Inc. is at the forefront of developing novel therapies that aim to redefine cancer treatment. By targeting critical mechanisms like NETs and leveraging its expertise in biologics, the company continues to make strides toward delivering impactful solutions for patients and healthcare providers.
Xenetic Biosciences (NASDAQ: XBIO) will present at the Virtual Investor 2023 Companies to Watch Event on January 17, 2023, at 10:00 AM ET. CEO Jeffrey Eisenberg will showcase the company's advancements in immune-oncology technologies aimed at treating hard-to-treat cancers. A live video webcast will be available on the company's Investors website page, with a replay accessible for 90 days post-event. Xenetic specializes in DNase platforms for cancer treatment and the XCART™ technology for personalized CAR T therapies.
Xenetic Biosciences (NASDAQ:XBIO) announced the appointment of Dr. Jonathan Spicer to its Scientific Advisory Board, enhancing its expertise in the role of neutrophil extracellular traps (NETs) in cancer biology. Dr. Spicer, an expert in neoadjuvant immunotherapy for lung cancer, will support the advancement of the Company's DNase platform, which aims to improve cancer treatment outcomes by targeting NETs. This collaboration is pivotal as Xenetic progresses towards a planned Phase 1 study, indicating potential growth in its innovative oncology technologies.
Xenetic Biosciences (NASDAQ: XBIO) reported its financial results for Q3 2022, highlighting progress in its DNase-based oncology platform targeting hard-to-treat cancers. The company ended the quarter with $13.8 million in cash. Notably, net loss was approximately $0.8 million, with R&D expenses down 48.9% to $0.4 million. The company also received $0.4 million in royalties, reflecting an 18.6% increase year-over-year. Xenetic remains focused on advancing its DNase program and collaborations aimed at enhancing cancer therapies.
Xenetic Biosciences (NASDAQ: XBIO) announced the signing of a patent assignment from CLS Therapeutics as part of a collaboration with CLS and VolitionRx (NYSE AMERICAN: VNRX) to develop NETs-targeted adoptive cell therapies for cancer. In exchange for the patent, Xenetic will issue 850,000 shares to CLS. This collaboration aims to combine Volition's Nu.Q technology and Xenetic's DNase-Armored CAR T platform, targeting various solid tumors where current therapies are ineffective. The partnership will also share proceeds from any resulting commercial products.
Xenetic Biosciences (NASDAQ: XBIO) announced the appointment of Allan Tsung, MD to its Scientific Advisory Board. Dr. Tsung, a leading expert in cancers of the liver, bile duct, and pancreas, brings extensive clinical and research experience, aiming to guide the company’s DNase-based oncology platform. His leadership at the University of Virginia and participation in numerous academic surgical organizations positions him to contribute significantly to Xenetic’s development strategies. This appointment is part of the company’s commitment to advancing innovative immune-oncology technologies to address unmet medical needs in cancer treatment.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference in New York, NY, from September 12-14, 2022. Jeffrey F. Eisenberg, the CEO, will present at the event, which will also feature virtual one-on-one meetings for registered investors. A video webcast of the presentation will be available on-demand starting September 12 at 7:00 AM ET, archived for 90 days. The Company is advancing innovative immune-oncology technologies, particularly for hard-to-treat cancers.
Xenetic Biosciences (NASDAQ: XBIO) reported its second quarter 2022 results, highlighting a significant in-licensing deal that expands its oncology pipeline with a focus on DNase-based therapies. The company aims to advance its DNase program towards a Phase 1 study targeting pancreatic carcinoma and other advanced solid tumors. Financially, Xenetic ended the quarter with $14.9 million in cash but posted a net loss of approximately $2.7 million. R&D expenses surged by 296.1% due to investments in the new DNase platform.
Xenetic Biosciences (NASDAQ: XBIO) and VolitionRx Limited (NYSE AMERICAN: VNRX) announced a collaboration to develop Neutrophil Extracellular Traps (NETs) targeted, adoptive cell therapies for cancer treatment. The program aims to evaluate the integration of Volition's Nu.Q® NETs Test with Xenetic's DNase-Armored CAR T platform to potentially address multiple solid tumor types. Volition will fund the research, sharing proceeds from commercialization. The collaboration highlights both companies' commitment to innovative cancer therapies and reflects Xenetic's recent acquisition of the DNase platform.
Xenetic Biosciences (NASDAQ: XBIO) has entered into a manufacturing agreement with Catalent Pharma Solutions to advance its DNase-based oncology platform aimed at enhancing treatment outcomes for solid tumors, including pancreatic carcinoma. The agreement facilitates cGMP manufacturing for Human DNase I, supporting the company's planned first-in-human study combining DNase with immune checkpoint inhibitors or chemotherapy. This collaboration signifies a strategic step towards developing innovative therapies for difficult-to-treat cancers.
Xenetic Biosciences (NASDAQ: XBIO) will host a Virtual Investor Innovation in Oncology Event on June 9, 2022, at 11:00 AM ET. The event features a moderated roundtable with the company's leadership and surgical oncology expert, Allan Tsung, MD. The discussion will cover their innovative DNase oncology platform targeting solid tumors and the personalized CAR T platform for B-Cell lymphomas. Investors can submit questions during the event. A live webcast will be available, and a replay will be accessible for 90 days after the event.
FAQ
What is the current stock price of Xenetic Biosciences (XBIO)?
What is the market cap of Xenetic Biosciences (XBIO)?
What does Xenetic Biosciences specialize in?
What is the DNase-based oncology platform?
What are Xenetic's key collaborations?
How does the PolyXen™ platform work?
What types of cancers is Xenetic targeting?
What differentiates Xenetic Biosciences from competitors?
Does Xenetic generate revenue?
What stage is Xenetic's DNase program in?
